3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
16
Phase 3
4
Phase 2
3
Phase 4
2
Phase 2/3
2
Phase 1/2
1
Status
Unknown
2
Recruiting
2
Completed
2
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
55
Carcinoma, Hepatocellular
40
Neoplasms
38
Polycystic Ovary Syndrome
27
Colorectal Neoplasms
24
Stomach Neoplasms
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Prostatic Neoplasms
16
Carcinoma, Non-Small-Cell Lung
16
Recurrence
13
Pancreatic Neoplasms
13
Lymphoma
13
Liver Neoplasms
13
Urinary Bladder Neoplasms
11
Leukemia, Myeloid, Acute
11
Esophageal Neoplasms
11
Leiomyoma
10
Colonic Neoplasms
10
Pain
9
Lung Neoplasms
9
Multiple Myeloma
8
Uterine Cervical Neoplasms
7
Neoplasm Metastasis
7
Lymphoma, Non-Hodgkin
7
Lymphoma, Follicular
7
Keratosis, Actinic
7
Infertility
7
Papillomavirus Infections
6
Pain, Postoperative
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Interventions
Spironolactone
1
Carvedilol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Unknown
×
Cardiotoxicity
×
Clear all
NCT04939883
2024-06-28
CardioTox
Hospital Sirio-Libanes
Phase 4
Unknown
1,018 enrolled
NCT06005259
2023-08-22
SPIROTOX
University of Sao Paulo
Phase 4
Unknown
264 enrolled